U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13N5O4
Molecular Weight 267.2417
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZIDOVUDINE

SMILES

Cc1cn([C@@]2([H])C[C@@]([H])([C@@]([H])(CO)O2)N=[N+]=[N-])c(=O)nc1O

InChI

InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H13N5O4
Molecular Weight 267.2417
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019910s033lbl.pdf

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Zidovudine, a structural analog of thymidine, is a prodrug that must be phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). It inhibits the activity of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. It competes with the natural substrate dGTP and incorporates itself into viral DNA. It is also a weak inhibitor of cellular DNA polymerase α and γ. Zidovudine is used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections. Zidovudine is marketed as Retrovir.

Originator

Curator's Comment:: Zidovudine had initially been synthesized by Dr. Jerome Horwitz and associates in 1964 at the Michigan Cancer Foundation as a potential anticancer agent

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RETROVIR

Approved Use

RETROVIR is a nucleoside analogue reverse transcriptase inhibitor indicated for: -- Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) -- Prevention of maternal-fetal HIV-1 transmission. (1.2)

Launch Date

543024000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.1 μg/mL
2.5 mg/kg 6 times / day steady-state, intravenous
dose: 2.5 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.2 μg/mL
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.55 μg/mL
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1 μg/mL
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.8 μg/mL
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.16 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.74 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.72 μg/mL
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1400 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.32 mg × h/L
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.65 mg × h/L
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.28 mg × h/L
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.31 mg × h/L
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.26 mg × h/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.39 mg × h/L
60 mg single, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.74 mg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.22 mg × h/L
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.33 mg × h/L
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.4 h
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 h
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 h
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.4 h
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.3 h
60 mg single, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.7 h
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
62%
2.5 mg/kg 6 times / day steady-state, intravenous
dose: 2.5 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Disc. AE: Anemia...
AEs leading to
discontinuation/dose reduction:
Anemia (grade 1, 1 patient)
Sources:
1000 mg 1 times / day steady, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: steady
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Other AEs: Depression...
Other AEs:
Depression (1 patient)
Sources:
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Disc. AE: Dizziness, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Dizziness (1 patient)
Diarrhoea (1 patient)
Sources:
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Disc. AE: Drowsiness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Sources:
36 g single, oral
Overdose
Dose: 36 g
Route: oral
Route: single
Dose: 36 g
Sources:
unhealthy, 35 years
Health Status: unhealthy
Age Group: 35 years
Sex: M
Sources:
Disc. AE: Seizure...
AEs leading to
discontinuation/dose reduction:
Seizure (1 patient)
Sources:
134 mg single, oral
Overdose
Dose: 134 mg
Route: oral
Route: single
Dose: 134 mg
Sources:
healthy, 4 day
Health Status: healthy
Age Group: 4 day
Sex: F
Sources:
Disc. AE: Metabolic acidosis exacerbated...
AEs leading to
discontinuation/dose reduction:
Metabolic acidosis exacerbated (1 patient)
Sources:
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Cardiac arrhythmia...
Other AEs: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cardiac arrhythmia (grade 5, 1 patient)
Other AEs:
Diarrhea (grade 3-4, 17%)
Sources:
40 g single, oral
Overdose
Dose: 40 g
Route: oral
Route: single
Dose: 40 g
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Nystagmus...
AEs leading to
discontinuation/dose reduction:
Nystagmus (1 patient)
Sources:
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Other AEs: Asthenia, Headache...
Other AEs:
Asthenia (9%)
Headache (63%)
Malaise (53%)
Anorexia (20%)
Constipation (6%)
Nausea (51%)
Vomiting (17%)
Anemia (1%)
Granulocytopenia (2%)
Sources:
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Other AEs: Fever, Hepatomegaly...
Other AEs:
Fever (25%)
Hepatomegaly (11%)
Nausea and vomiting (8%)
Diarrhea (8%)
Stomatitis (6%)
Splenomegaly (5%)
Cough (15%)
Breath sounds abnormal (7%)
Ear disorders NEC (7%)
Congestion nasal (8%)
Skin rash (12%)
Lymphadenopathy (9%)
Neutropenia (8%)
Thrombocytopenia (1%)
ALT (grade 3, 1%)
Lipase (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia grade 1, 1 patient
Disc. AE
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Depression 1 patient
1000 mg 1 times / day steady, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: steady
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Diarrhoea 1 patient
Disc. AE
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Dizziness 1 patient
Disc. AE
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Drowsiness 1 patient
Disc. AE
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
Seizure 1 patient
Disc. AE
36 g single, oral
Overdose
Dose: 36 g
Route: oral
Route: single
Dose: 36 g
Sources:
unhealthy, 35 years
Health Status: unhealthy
Age Group: 35 years
Sex: M
Sources:
Metabolic acidosis exacerbated 1 patient
Disc. AE
134 mg single, oral
Overdose
Dose: 134 mg
Route: oral
Route: single
Dose: 134 mg
Sources:
healthy, 4 day
Health Status: healthy
Age Group: 4 day
Sex: F
Sources:
Diarrhea grade 3-4, 17%
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Cardiac arrhythmia grade 5, 1 patient
Disc. AE
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nystagmus 1 patient
Disc. AE
40 g single, oral
Overdose
Dose: 40 g
Route: oral
Route: single
Dose: 40 g
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Anemia 1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vomiting 17%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Granulocytopenia 2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Anorexia 20%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 51%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Malaise 53%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Constipation 6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 63%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Asthenia 9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Thrombocytopenia 1%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Hepatomegaly 11%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Skin rash 12%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Cough 15%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Fever 25%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Lipase 3%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Splenomegaly 5%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Stomatitis 6%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Breath sounds abnormal 7%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Ear disorders NEC 7%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Congestion nasal 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Diarrhea 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Nausea and vomiting 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Neutropenia 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
Lymphadenopathy 9%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
ALT grade 3, 1%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 <400 uM]
no [IC50 <500 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
no
no
no
no
weak [IC50 31.34 uM]
yes [Ki 1200 uM]
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 770 uM]
yes (pharmacogenomic study)
Comment: Km (Pooled HLMs) = 1.4 mM; The carriers of UGT2B7*1c had 57% lower mean AUC (P = 0.029, unpaired t-test), 196% higher mean CL/F (P = 0.004, unpaired t-test) (Figure 3B), and 67% shorter mean elimination half-life (P = 0.030, unpaired t-test) compared with non-carriers.
minor
minor
no
no
no
no
no
no
no
no
no
yes [Km 145.1 uM]
yes [Km 151.8 uM]
yes [Km 2400 uM]
yes [Km 26.8 uM]
yes [Km 45.9 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Anti-HIV activity and mechanism of action of macrocyclic diamide SRR-SB3.
1998 Dec
Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols.
1998 Oct-Nov
In vitro anti-hepatitis B virus activities of 5"-O-myristoyl analogue derivatives of 3"-fluoro-2",3"-dideoxythymidine (FLT) and 3"-azido-2",3"-dideoxythymidine (AZT).
1998 Sep-Dec
Synthesis and anti-HIV activity of unusual nucleoside oxanosine derivatives.
1999
Synthesis and antiviral activity of 1-[1,5-dialkyl-1H-1,2,4-triazol-3-yl)methyl]thymines.
1999 Apr
Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient.
1999 Apr
Chicoric acid analogues as HIV-1 integrase inhibitors.
1999 Apr 22
Synthesis of AZT-alpha-Borano-5'-diphospho-hexoses.
1999 Apr-May
"Mixed inhibitors" of HIV-reverse transcriptase: synthesis and antiviral activity.
1999 Apr-May
Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
1999 Aug
Charge modification of plasma and milk proteins results in antiviral active compounds.
1999 Dec
Inhibition of beta-globin gene expression by 3'-azido-3'-deoxythymidine in human erythroid progenitor cells.
1999 Dec 31
Zidovudine (AZT) induced alterations in mitochondrial biogenesis in rat striated muscles.
1999 Jan
Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis.
1999 Jan
PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms.
1999 Jan
Substituted 7H-pyrido[4,3-c]carbazoles with potent anti-HIV activity.
1999 Jan 18
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
1999 Jul
Synthesis and anti-HIV activity of some novel arylphosphate and H-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine.
1999 Jul
Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.
1999 Jul 1
A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
1999 Jun
Synthesis, lipophilicity and anti-HIV activity of a new brominated analog of zidovudine.
1999 Mar
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
1999 Mar
A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor.
1999 Mar 22
Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase.
1999 May
Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
1999 Nov
Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice.
1999 Nov 15
Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
1999 Nov 20
Synthesis and anti-retroviral activity of O,O'-bis(3'-azido-2',3'-dideoxythymidin-5'-yl) phosphoramidate derivatives.
1999 Oct
Synthesis of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides as potential antiviral agents.
1999 Oct
Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT.
1999 Oct 19
Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
1999 Oct 21
Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
1999 Sep
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.
1999 Sep 25
Prophylactic contraceptives for HIV/AIDS.
1999 Sep-Oct
Synthesis and biological activity of N-acylphenothiazines.
2000 Apr
Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus.
2000 Apr
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
2000 Apr 10
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
2000 Aug
Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity.
2000 Jan 3
Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA- and nuclear DNA-encoded subunits.
2000 Jul
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
2000 Jul
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
2000 Jul 4
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
2000 Jun 5
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents.
2000 Mar
Spiropentane mimics of nucleosides: analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, isomeric assignment, and biological activity.
2000 Mar 10
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
2000 May
Patents

Sample Use Guides

Treatment of HIV-1 infection:
Route of Administration: Oral
The antiviral activity of CD8(+) cells from 2 LTSs was inhibited by 5 uM of zidovudine.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:21 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:21 UTC 2021
Record UNII
4B9XT59T7S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZIDOVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
ZIDOVUDINE [EP MONOGRAPH]
Common Name English
BW-A509U
Code English
AZIDOTHYMIDINE
Systematic Name English
3'-DEOXY-3'-AZIDOTHYMIDINE
Systematic Name English
THYMIDINE, 3'-AZIDO-3'-DEOXY-
Systematic Name English
ZDV
Common Name English
ZIDOVUDINE [MI]
Common Name English
COMBIVIR COMPONENT ZIDOVUDINE
Common Name English
ZIDOVUDINE [USP-RS]
Common Name English
AZT
Common Name English
ZIDOVUDINE COMPONENT OF TRIZIVIR
Brand Name English
TRIZIVIR COMPONENT ZIDOVUDINE
Brand Name English
ZIDOVUDINE [IARC]
Common Name English
ZIDOVUDINE [WHO-DD]
Common Name English
ZIDOVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
ZIDOVUDINE COMPONENT OF COMBIVIR
Common Name English
ZIDOVUDINE [EP]
Common Name English
ZIDOVUDINE [USAN]
Common Name English
ZIDOVUDINE [JAN]
Common Name English
COMPOUND S
Code English
ZIDOVUDINE [EMA EPAR]
Common Name English
ZIDOVUDINE [ORANGE BOOK]
Common Name English
ZIDOVUDINE [VANDF]
Common Name English
RETROVIR
Brand Name English
3'-AZIDO-3'-DEOXYTHYMIDINE
Systematic Name English
ZIDOVUDINE [MART.]
Common Name English
ZIDOVUDINE [USP MONOGRAPH]
Common Name English
3'-AZT
Common Name English
ZIDOVUDINE [WHO-IP]
Common Name English
3'-AZIDOTHYMIDINE
Systematic Name English
ZIDOVUDINE [HSDB]
Common Name English
ZIDOVUDINE [INN]
Common Name English
BW-A-509U
Code English
NSC-602670
Code English
ZIDOVUDINUM [WHO-IP LATIN]
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
FDA ORPHAN DRUG 8185
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-VATC QJ05AR04
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-ATC J05AR05
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-ATC J05AF01
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NDF-RT N0000175462
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-VATC QJ05AR01
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-ATC J05AR04
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NCI_THESAURUS C97452
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NDF-RT N0000009947
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-ATC J05AR01
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-VATC QJ05AR05
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
WHO-VATC QJ05AF01
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
LIVERTOX 1047
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
ZIDOVUDINE
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY Description: A white or brownish powder. Solubility: Soluble in ethanol (~750 g/l) TS, sparingly soluble in water. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Zidovudine should be kept in a tightly closed container, protected from light. Additional information: Zidovudine may exhibit polymorphism. Definition: Zidovudine contains not less than 97.0% and not more than 103.0% of C10H13N5O4, calculated with reference to the dried substance.
NCI_THESAURUS
C947
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
DRUG CENTRAL
2861
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
INN
6118
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
CAS
30516-87-1
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
MESH
D015215
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
LACTMED
Zidovudine
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
IUPHAR
4825
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
FDA UNII
4B9XT59T7S
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
RXCUI
11413
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00495
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
USP_CATALOG
1724500
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY USP-RS
EPA CompTox
30516-87-1
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
EVMPD
SUB00153MIG
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
MERCK INDEX
M11592
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
ZIDOVUDINE
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL129
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
PUBCHEM
35370
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
HSDB
6515
Created by admin on Fri Jun 25 20:54:21 UTC 2021 , Edited by admin on Fri Jun 25 20:54:21 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TRANSPORTER -> NON-SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> NON-SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
AMOUNT FORMED FOLLOWING ADMINISTRATION
MINOR
METABOLITE TOXIC -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
AMOUNT OF EXCRETED
MAJOR
Related Record Type Details
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity C (thymine) about 0.3. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.6, is not greater than four times the area of the principal peak in the chromatogram obtained with solution (2) (2.0%).
IMPURITY -> PARENT
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity B about 1.2. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity B, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity A (stavudine) about 0.4;. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity A, when multiplied by a correction factor of 0.9, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).
IMPURITY -> PARENT
IMPURITY -> PARENT
Not Specified
IMPURITY -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Populations
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Polpulation
PHARMACOKINETIC